Immunoglobulin A (IgA) Nephropathy Therapeutics Market Report 2026

Immunoglobulin A (IgA) Nephropathy Therapeutics Market Overview

• Immunoglobulin A (IgA) Nephropathy Therapeutics market size has reached to $1.09 billion in 2025 • Expected to grow to $1.91 billion in 2030 at a compound annual growth rate (CAGR) of 12% • Growth Driver: Prevalence Of Chronic Kidney Disease Fueling The Market Growth Due To Aging Demographics And Rising Diabetes Prevalence • Market Trend: Advancements In Targeted Biologic Therapies For Immune-Mediated Kidney Disorders • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Immunoglobulin A (IgA) Nephropathy Therapeutics Market?

Immunoglobulin A (IgA) nephropathy therapeutics refer to pharmaceutical treatments and biologic therapies developed to manage Immunoglobulin A nephropathy, a kidney disorder caused by the buildup of IgA antibodies in the kidneys. These therapeutics are designed to reduce inflammation, slow disease progression, control proteinuria, and preserve kidney function. They include targeted therapies, supportive treatment formulations, and advanced drug delivery approaches aimed at improving patient outcomes and reducing the risk of kidney failure. The main drug classes of immunoglobulin A (IgA) nephropathy therapeutics include corticosteroids, immunosuppressants, renin angiotensin system inhibitors, biologics, and other drug classes. Corticosteroids refer to anti-inflammatory drugs used to reduce kidney inflammation and slow disease progression in IgA nephropathy. These treatments are categorized by treatment type including supportive treatment and disease specific treatment and are administered through oral and injectable routes. They are distributed through hospital pharmacies, retail pharmacies, online pharmacies, and other distribution channels and are utilized by end users including hospitals, specialty clinics, and homecare settings.

What Is The Immunoglobulin A (IgA) Nephropathy Therapeutics Market Growth Forecast?

The immunoglobulin A (IGA) nephropathy therapeutics market size is expected to see rapid growth in the next few years. It will grow to $1.91 billion in 2030 at a compound annual growth rate (CAGR) of 12.0%. The growth in the forecast period can be attributed to growth in precision medicine and biomarker based nephrology treatments, increasing adoption of biologics and complement inhibitors, rising clinical trials for novel igA nephropathy therapies, expansion of early screening programs for kidney diseases, increasing investment in renal drug development pipelines. Major trends in the forecast period include targeted complement inhibition therapies for igA nephropathy progression control, biologic monoclonal antibody development for immune mediated kidney inflammation reduction, biomarker driven precision medicine approaches for early igA nephropathy diagnosis and stratification, novel oral small molecule therapies for proteinuria reduction and renal protection, advanced drug delivery systems for sustained renal targeting and improved therapeutic efficacy.

Global Immunoglobulin A (IgA) Nephropathy Therapeutics Market Segmentation

1) By Drug Class: Corticosteroids, Immunosuppressants, Renin Angiotensin System Inhibitors, Biologics, Other Drug Classes 2) By Treatment Type: Supportive Treatment, Disease Specific Treatment 3) By Route Of Administration: Oral, Injectable 4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Other Distribution Channel 5) By End User: Hospitals, Specialty Clinics, Homecare Settings Subsegments: 1) By Corticosteroids: Systemic Corticosteroids, Oral Corticosteroids, High Dose Corticosteroid Therapy, Tapering Dose Corticosteroid Regimens 2) By Immunosuppressants: Calcineurin Inhibitors, Antimetabolites, Alkylating Agents, Selective Immunosuppressive Agents 3) By Renin Angiotensin System Inhibitors: Angiotensin Converting Enzyme Inhibitors, Angiotensin Two Receptor Blockers, Direct Renin Inhibitors, Combination Renin Angiotensin System Therapies 4) By Biologics: Monoclonal Antibodies, Complement Inhibitors, Cytokine Targeting Biologics, Recombinant Protein Therapies 5) By Other Drug Classes: Supportive Therapies, Anti Inflammatory Agents, Lipid Lowering Agents, Emerging Small Molecule Therapies

What Is The Driver Of The Immunoglobulin A (IgA) Nephropathy Therapeutics Market?

The increasing incidence of chronic kidney disease (CKD) is expected to propel the growth of the immunoglobulin A (IgA) nephropathy therapeutics market going forward. Chronic kidney disease is a progressive condition where kidneys become damaged and lose their ability to filter blood effectively over time. The chronic kidney diseases prevalence is increasing due to the growing aging population, as kidney function naturally declines with age and older adults are more susceptible to diabetes and hypertension which are leading causes of kidney damage. Immunoglobulin A (IgA) nephropathy therapeutics contribute to chronic kidney disease (CKD) management by targeting the underlying immune-mediated glomerular inflammation and proteinuria in IgA nephropathy, thereby slowing disease progression, preserving long-term renal function, and reducing the risk of patients advancing to end-stage kidney disease. For instance, in June 2023, according to Kidney Research UK, a UK-based charitable organization, an estimated 7.19 million people in the UK were affected by chronic kidney disease in 2023, representing more than 10% of the UK population and projected to increase to 7.61 million people by 2033. Therefore, the increasing incidence of chronic kidney disease (CKD) is driving the growth of the immunoglobulin A (IgA) nephropathy therapeutics industry.

Key Players In The Global Immunoglobulin A (IgA) Nephropathy Therapeutics Market

Major companies operating in the immunoglobulin a (iga) nephropathy therapeutics market are Pfizer Inc., F. Hoffmann-La Roche Ltd., Sanofi S.A., AstraZeneca PLC, Novartis AG, Bristol-Myers Squibb Company, Vertex Pharmaceuticals Incorporated, Otsuka Holdings Co. Ltd., Jiangsu Hengrui Pharmaceuticals Co. Ltd., Boehringer Ingelheim, Biogen Inc., Alnylam Pharmaceuticals Inc., Ionis Pharmaceuticals Inc., Travere Therapeutics Inc., RemeGen Co. Ltd., Arrowhead Pharmaceuticals Inc., Apellis Pharmaceuticals Inc., BioCryst Pharmaceuticals Inc., Vera Therapeutics Inc., Transcenta Holding Limited, Shanghai Alebund Pharmaceuticals Co. Ltd., Kira Pharmaceuticals Inc., Purespring Therapeutics Ltd.

Global Immunoglobulin A (IgA) Nephropathy Therapeutics Market Trends and Insights

Major companies operating in the immunoglobulin A (IgA) nephropathy therapeutics market are focusing on developing innovative targeted biologic therapies, such as anti-april monoclonal antibodies to reduce abnormal IgA production, slow disease progression, and preserve kidney function in patients with primary IgA nephropathy. Anti-april monoclonal antibodies are targeted biologic drugs that block APRIL (a protein involved in immune signaling) to reduce abnormal IgA antibody production, helping to lower kidney inflammation, reduce protein buildup in urine, and slow disease progression in IgA nephropathy. For instance, in November 2025, Otsuka Pharmaceutical Co. Ltd., a Japan-based healthcare company, received U.S. Food and Drug Administration accelerated approval for Voyxact (sibeprenlimab-szsi), a novel anti-APRIL monoclonal antibody therapy for primary immunoglobulin A nephropathy. The treatment is designed to inhibit APRIL-mediated signaling pathways, thereby reducing pathogenic IgA production and immune complex deposition in the kidneys. It is administered as a biologic therapy aimed at slowing kidney function decline and reducing proteinuria in adults with IgA nephropathy at risk of disease progression, representing a significant advancement in targeted renal disease management.

What Are Latest Mergers And Acquisitions In The Immunoglobulin A (IgA) Nephropathy Therapeutics Market?

In January 2024, Novartis AG, a Switzerland-based pharmaceutical company, acquired SanReno Therapeutics Co. Ltd. for an undisclosed amount. With this acquisition, Novartis AG aims to strengthen its late-stage nephrology pipeline by securing rights to advanced therapies targeting Immunoglobulin A Nephropathy (IgAN), thereby accelerating the development and commercialization of innovative treatments for rare and progressive kidney diseases. SanReno Therapeutics Co. Ltd. is a China-based clinical-stage biopharmaceutical company that specializes in developing therapeutics for immunoglobulin A (IgA) nephropathy.

Regional Outlook

North America was the largest region in the immunoglobulin A (IgA) nephropathy therapeutics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Immunoglobulin A (IgA) Nephropathy Therapeutics Market?

The immunoglobulin A (IgA) nephropathy therapeutics market consists of sales of oral therapeutic drugs, injectable therapies, targeted-release formulations, antibody-based therapies, complement pathway inhibitors, anti-inflammatory agents, and kidney disease management drugs. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Immunoglobulin A (IgA) Nephropathy Therapeutics Market Report 2026?

The immunoglobulin A (IGA) nephropathy therapeutics market research report is one of a series of new reports from The Business Research Company that provides immunoglobulin A (IGA) nephropathy therapeutics market statistics, including immunoglobulin A (IGA) nephropathy therapeutics industry global market size, regional shares, competitors with a immunoglobulin A (IGA) nephropathy therapeutics market share, detailed immunoglobulin A (IGA) nephropathy therapeutics market segments, market trends and opportunities, and any further data you may need to thrive in the immunoglobulin A (IGA) nephropathy therapeutics industry. This immunoglobulin A (IGA) nephropathy therapeutics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.